Vital nabs FDA approval for universal viewer

Justine Varieur Cadet | | Health Imaging | Screening
Vital Images, a subsidiary of Toshiba Medical Systems Group that develops advanced visualization and analysis technologies for healthcare providers, has received 510(k) clearance from the FDA for VitreaView, a universal viewer that provides uniform access to patient images. VitreaView is designed for access through the EMR, EHR and health information exchange (HIE).

VitreaView’s technology allows for image distribution through a zero-footprint and zero download viewing, according to the Minneapolis-based company. Users accessing VitreaView can use web-enabled devices, including Windows or Mac-based systems, for review of DICOM and non-DICOM medical images.

Additionally, Vital said that IT administrators can leverage virtualization for deployment along with VitreaView's capability to manage access to multiple databases, thus providing a universal imaging layer at an enterprise level.

Justine Varieur Cadet

Related Content

Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility

Around the web

Radiology Business
AI can help radiology standardize image exam data labeling

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.

Radiology Business
The biggest obstacles facing radiology business managers in 2025

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.